TY - JOUR
T1 - Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction
AU - MANATEC-02 collaborative group
AU - Faron, Matthieu
AU - Cheugoua-Zanetsie, Armel Maurice
AU - Thirion, Pierre
AU - Nankivell, Matthew
AU - Winter, Kathryn
AU - Cunningham, David
AU - Van der Gaast, Ate
AU - Law, Simon
AU - Langley, Ruth
AU - de Vathaire, Florent
AU - Valmasoni, Michele
AU - Mauer, Muriel
AU - Roth, Jack
AU - Gebski, Val
AU - Burmeister, Bryan H.
AU - Paoletti, Xavier
AU - van Sandick, Johanna
AU - Fu, Jianhua
AU - Ducreux, Michel
AU - Blanchard, Pierre
AU - Tierney, Jayne
AU - Pignon, Jean Pierre
AU - Michiels, Stefan
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous cell carcinoma, making strong conclusions hard to obtain. The primary objective of this individual participant data meta-analysis was to investigate the effect of neoadjuvant chemotherapy on overall survival (OS). Patients and methods: Eligible trials should have closed to accrual before 2016 and compared neoadjuvant chemotherapy and surgery (CS) to surgery alone. All relevant published and unpublished trials were identified via searches of electronic databases, conference proceedings and clinical trial registers. The main end-point was OS. Investigators were contacted to obtain the individual patient data, which was recorded, harmonised and checked. A random-effects Cox model, stratified by trial, was used for meta-analysis and subgroup analyses were preplanned. Results: 16 trials were identified as eligible. Individual patient data were obtained from 12 trial and 2478 patients. CS was associated with an improved OS versus surgery, hazard ratio (HR) = 0.83 [0.72–0.96], p < 0.0001, translating to an absolute benefit of 5.7% at 5-years from 16.8% to 22.5%. Treatment effects did not vary substantially between adenocarcinoma (HR = 0.73 [0.62–0.87]) and squamous cell carcinoma (HR = 0.91 [0.76–1.08], interaction p = 0.26). A somewhat more pronounced effect was observed in gastro-oesophageal junction (HR = 0.68 [0.50–0.93]) versus TE (HR = 0.87 [0.75–1.00], interaction p = 0.07). CS was also associated with a greater disease-free survival (HR = 0.74 [0.64–0.85], p < 0.001). Conclusions: Neoadjuvant chemotherapy conferred a better OS than surgery alone and should be considered in all anatomical location and histological subtypes.
AB - Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous cell carcinoma, making strong conclusions hard to obtain. The primary objective of this individual participant data meta-analysis was to investigate the effect of neoadjuvant chemotherapy on overall survival (OS). Patients and methods: Eligible trials should have closed to accrual before 2016 and compared neoadjuvant chemotherapy and surgery (CS) to surgery alone. All relevant published and unpublished trials were identified via searches of electronic databases, conference proceedings and clinical trial registers. The main end-point was OS. Investigators were contacted to obtain the individual patient data, which was recorded, harmonised and checked. A random-effects Cox model, stratified by trial, was used for meta-analysis and subgroup analyses were preplanned. Results: 16 trials were identified as eligible. Individual patient data were obtained from 12 trial and 2478 patients. CS was associated with an improved OS versus surgery, hazard ratio (HR) = 0.83 [0.72–0.96], p < 0.0001, translating to an absolute benefit of 5.7% at 5-years from 16.8% to 22.5%. Treatment effects did not vary substantially between adenocarcinoma (HR = 0.73 [0.62–0.87]) and squamous cell carcinoma (HR = 0.91 [0.76–1.08], interaction p = 0.26). A somewhat more pronounced effect was observed in gastro-oesophageal junction (HR = 0.68 [0.50–0.93]) versus TE (HR = 0.87 [0.75–1.00], interaction p = 0.07). CS was also associated with a greater disease-free survival (HR = 0.74 [0.64–0.85], p < 0.001). Conclusions: Neoadjuvant chemotherapy conferred a better OS than surgery alone and should be considered in all anatomical location and histological subtypes.
KW - Chemotherapy
KW - Gastro-oesophageal junction
KW - Individual patient data
KW - Meta-analysis
KW - Oesophageal cancer
KW - Preoperative
UR - http://www.scopus.com/inward/record.url?scp=85115248373&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.08.014
DO - 10.1016/j.ejca.2021.08.014
M3 - Article
C2 - 34555647
AN - SCOPUS:85115248373
SN - 0959-8049
VL - 157
SP - 278
EP - 290
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -